RHOPHYLAC 300 Israel - engelsk - Ministry of Health

rhophylac 300

csl behring ltd., israel - anti-d immunoglobulins - solution for injection - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood sampling) or other intrauterine procedures (e.g. insertion of shunts embryo reduction) external version of the fetus and therapeutic abortion. incidents during pregnancy such as antepartum haemorrhage spontaneous abortion ruptured tubal pregnancy ectopic pregnancy stillbirths intrauterine death and abdominal trauma. treatment of rh (d) -negative persons after incompatible transfusions of rh (d)-positive blood or erythrocyte concentrate: prevention of rh (d) immunisation in rh (d)-negative persons who for any reason have been given blood or blood components containing rh (d)-positive red cells.

CSL Rh(D) IMMUNOGLOBULIN VF (human) 250 IU injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl rh(d) immunoglobulin vf (human) 250 iu injection vial

csl behring australia pty ltd - anti-d rho immunoglobulin, quantity: 250 iu; anti-d rho immunoglobulin, quantity: 10 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - rh(d) immunoglobulin is indicated for the prevention of rh sensitisation in rh(d)negative females at or below child bearing age.

Rhesonativ 625 IU/ml, solution for injection Irland - engelsk - HPRA (Health Products Regulatory Authority)

rhesonativ 625 iu/ml, solution for injection

octapharma (ip) sprl - anti-d immunoglobulin - solution for injection - 625 international unit(s)/millilitre - specific immunoglobulins; anti-d (rh) immunoglobulin

Rhophylac 300micrograms / 2ml solution for injection in pre-filled syringe Malta - engelsk - Medicines Authority

rhophylac 300micrograms / 2ml solution for injection in pre-filled syringe

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - anti, d immunoglobulin, human - solution for injection in a pre-filled syringe - anti-d immunoglobulin, human 750 iu - immune sera and immunoglobulins

SPRAVATO esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution Australia - engelsk - Department of Health (Therapeutic Goods Administration)

spravato esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution

janssen-cilag pty ltd - esketamine hydrochloride, quantity: 32.3 mg (equivalent: esketamine, qty 28 mg) - spray, nasal - excipient ingredients: disodium edetate; citric acid monohydrate; water for injections; sodium hydroxide - spravato is indicated for treatment resistant depression (major depressive disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,spravato is to be initiated in conjunction with a newly initiated oral antidepressant.

KAM-RHO (D) I.V. Israel - engelsk - Ministry of Health

kam-rho (d) i.v.

kamada ltd, israel - anti-d immunoglobulins - solution for injection - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.

Rhophylac 300 micrograms / 2 ml, solution for injection in pre-filled syringe Irland - engelsk - HPRA (Health Products Regulatory Authority)

rhophylac 300 micrograms / 2 ml, solution for injection in pre-filled syringe

csl behring gmbh - human anti-d immunoglobulin - solution for injection in pre-filled syringe - 300 microgram(s) - specific immunoglobulins; anti-d (rh) immunoglobulin